^
Association details:
| Biomarker: | KRAS G12R |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo
Excerpt:
Our results showed that dasatinib exhibits prominent cytostatic activity both in vitro and in vivo against thyroid cancer cell lines with RET/PTC rearrangement (BHP2-7) and KRAS mutation (Cal62).
DOI:
10.3892/ol.2012.579
